Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Meningioma × vistusertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 2 Solid Tumor 2 Carcinoma, Non-Small-Cell Lung 2 Small Cell Lung Carcinoma 1 Recurrence 1 Non-small Cell Lung Cancer Metastatic 1 Meningioma 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Lung Neoplasms 1 Estrogen Receptor Positive Breast Cancer 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Breast Neoplasms 1 Adenocarcinoma 1

Interventions

Hydroxyurea 7 Everolimus 6 lutetium Lu 177 dotatate 5 Bevacizumab 5 Magnetic Resonance Spectroscopy 4 pembrolizumab 3 abemaciclib 3 Sunitinib 3 Imatinib Mesylate 3 gallium Ga 68 dotatate 2 arginyllysine 2 aldesleukin 2 Whole Body Imaging 2 Specimen Handling 2 Radiotherapy 2 Octreotide 2 Nivolumab 2 Cyclophosphamide 2 Amino Acids 2 90Y-octreotide, DOTA-Tyr(3)- 2 vistusertib 1 vatalanib 1 tozuleristide 1 sargramostim 1 regorafenib 1 pasireotide 1 olaparib 1 neratinib 1 fludarabine phosphate 1 fludarabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03071874 2022-10-18

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

Massachusetts General Hospital

Phase 2 Unknown

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡